House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Dermatology

Autoimmune blistering diseases in children and adolescents

EADV · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The EADV paediatric autoimmune blistering guideline describes rare disorders whose diagnosis and management require specialist paediatric dermatology. This focused summary covers clinical recognition, confirmatory investigations and selected narrative management principles for linear IgA disease, bullous pemphigoid, mucous membrane pemphigoid, dermatitis herpetiformis and pemphigus. The guideline is consensus-based: paediatric controlled-treatment evidence is scarce, and therapies are generally used off-label.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Recognise disease and involve specialist care

  • Consider autoimmune blistering disease in a child with progressive, widespread or recurrent blistering after infectious and inherited causes have been excluded. Alternatives include infection, inherited blistering disorders and drug reactions; investigate relevant alternatives before ordering autoimmune blistering investigations. [1]
  • Take a detailed history of age at onset, infection, medicines, vaccination, trauma, maternal disease, family history and associated mucosal or systemic features. Use the temporal history to investigate a possible trigger rather than assuming causation from coincidence alone. [1]
  • Manage with specialist paediatric dermatology and a multidisciplinary approach appropriate to organ involvement. Consider school performance, quality of life, psychological effects and long-term disease/treatment toxicity; children cannot simply be treated as smaller adults. [1]

Recognise and manage linear IgA disease

  • Suspect childhood linear IgA dermatosis with grouped tense blisters on the lower abdomen, perioral area or perineum, often in an annular crown-of-jewels pattern. Neonatal disease warrants particular caution because mucosal and systemic involvement can cause severe morbidity. [1]
  • Confirm suspected linear IgA dermatosis using histopathology, direct immunofluorescence and serology. Direct immunofluorescence typically shows linear IgA; predominant mucosal lesions favour mucous membrane pemphigoid, while predominant typeVII-collagen IgA reactivity favours IgA epidermolysis bullosa acquisita. [1]
  • Treat an untreated infection preceding linear IgA disease and immediately stop a medicine suspected as its trigger. Mild cases may be managed as outpatients, but generalised rapidly progressive disease with oral involvement needs hospital care and nutritional/supportive assessment. [1]
  • For moderate-to-severe childhood linear IgA disease, dapsone is the narrative first-line treatment. Exclude G6PD deficiency, start at a low dose and titrate to response/tolerance with close monitoring for haemolysis and methaemoglobinaemia; the dose and surveillance plan require specialist prescribing. [1]
  • Individualise treatment duration in linear IgA disease to severity, response and course. There is no agreed fixed treatment duration, so apparent early improvement is not a universal stopping rule. [1]

Assess bullous and mucosal pemphigoid carefully

  • Consider bullous pemphigoid with itchy tense blisters and urticarial lesions; infantile disease often affects acral sites, palms, soles and face. Confirm with direct immunofluorescence and appropriate serum autoantibody testing rather than morphology alone. [1]
  • For bullous pemphigoid, the source describes hospitalisation under joint dermatology and paediatric care for children with severe, generalised disease, poor intake from oral involvement and associated comorbidities such as florid infection or systemic illness. Be cautious with prolonged corticosteroid treatment in infants and young children. [1]
  • Mucous membrane pemphigoid requires exclusive or predominant mucosal disease and can scar. In ocular or genital disease, use joint care with paediatric ophthalmology or gynaecology; vulvar disease also requires differentiation from lichen sclerosus, trauma and abuse. [1]
  • For isolated ocular mucous membrane pemphigoid, repeatedly negative direct immunofluorescence and serology do not automatically exclude the diagnosis: the source accepts a clinical diagnosis only after relevant alternatives have been excluded clinically and histologically. Specialist biopsy selection may use uninvolved oral mucosa rather than conjunctiva. [1]

Confirm dermatitis herpetiformis before altering tests

  • Suspect dermatitis herpetiformis with recurrent symmetrical, very itchy papules/vesicles on elbows, knees, back or buttocks; acral purpura may also occur in children. Positive direct immunofluorescence is required for confirmation because coeliac serology and routine histology alone are insufficiently specific for this skin disease. [1]
  • Until diagnostic assessment for dermatitis herpetiformis is complete, limit treatment because both gluten withdrawal and dapsone may alter test results. Once confirmed, a strict lifelong gluten-free diet is the cornerstone of treatment. [1]
  • For dermatitis herpetiformis rash not responding to the gluten-free diet, the source identifies dapsone as the treatment of choice. Titrate to clinical response and closely monitor both efficacy and adverse effects; this is not a substitute for maintaining the diet. [1]

Recognise pemphigus and minimise treatment harm

  • Suspect pemphigus vulgaris in pre-adolescent children or teenagers with mucosal erosions, even if isolated, with or without flaccid skin blisters. Pemphigus foliaceus more often causes crusted erosions in seborrhoeic sites without mucosal involvement; severe erythrodermic disease can be life-threatening. [1]
  • In paediatric pemphigus, monitor clinical evolution alongside anti-desmoglein ELISA levels, which can help assess response and relapse risk. Keep systemic corticosteroid duration as short as possible, but taper gradually over months; no fixed taper regimen has been validated in children. [1]

Limitations and use

  • This focused summary does not provide the complete disease-specific treatment ladders, pretreatment investigations, vaccination plan or detailed drug doses. Rare paediatric blistering diseases need specialist confirmation and monitoring rather than empirical escalation from a general summary.
  • The guideline is based largely on case series and expert consensus; off-label paediatric therapy, limited evidence and cumulative toxicity require individual benefit–risk discussion. EBA and paraneoplastic pemphigus treatment protocols are outside this summary.
  • In India, access to direct immunofluorescence, specialised antibody assays and paediatric dermatology may determine referral arrangements. Negative tests must be interpreted in the correct clinical and biopsy context.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Autoimmune blistering diseases in children and adolescents

    Selected recommendation material consulted

S2k guideline

Publication details

Issuing organisation
EADV
First published
12 February 2026
Resource type
S2k guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Recognise disease and involve specialist care
  • Recognise and manage linear IgA disease
  • Assess bullous and mucosal pemphigoid carefully
  • Confirm dermatitis herpetiformis before altering tests
  • Recognise pemphigus and minimise treatment harm
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House